Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 1/20 | 0.49 |
| ▸ | CTSA | P10619 | 5/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | FYN | P06241 | 4/20 | 0.47 |
| ▸ | BRAF | P15056 | 4/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14003503 | 0.83 | HSD17B10 (0.56) | POLBKITMAPK1FYNBRAF | |
| SCHEMBL6742199 | 0.80 | ALDH1A1 (0.52) | POLBKITMAPK1FYNBRAF | |
| SCHEMBL22130625 | 0.80 | KMT2A (0.55) | POLBKITMAPK1FYNBRAF | |
| SCHEMBL13986211 | 0.80 | NQO2 (0.55) | POLBNQO2MEN1KMT2AMAPT | |
| SCHEMBL16710317 | 0.79 | CTSA (0.49) | CTSA | |
| SCHEMBL12919978 | 0.78 | CYP17A1 (0.60) | NQO2MEN1KMT2A | |
| SCHEMBL16710321 | 0.77 | CTSA (0.49) | CTSAFYN | |
| SCHEMBL104492 | 0.76 | ALDH1A1 (0.59) | POLBMEN1KMT2A | |
| SCHEMBL18084774 | 0.76 | CTSA (0.50) | KITCTSAMEN1KMT2A | |
| SCHEMBL6934499 | 0.76 | HDAC4 (0.50) | CTSA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | UNIVERSITY OF KANSAS (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2015070091-A1 | BIPHENYLAMIDE DERIVATIVE HSP90 INHIBITORS | THE UNIVERSITY OF KANSAS (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689344-B2 | Biphenylamide derivative Hsp90 inhibitors | HSP90AB1, HSP90AA1, HSP90AB2P | POLB 1971/4885KIT 4727/4885CTSA 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.